Clinical trials
Gene Therapy clinical trials
Below are recruiting gene therapy clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06928701Recruiting
Diet and exercise for early breast cancer before surgery
This trial tests whether a personalized nutrition and exercise program can improve treatment response by changing how your body and immune system react to breast cancer before surgery. It is for women newly diagnosed with early-stage breast cancer who will receive neoadjuvant therapy (treatment before surgery).
Novara, NovaraAges 18 years+ - NCT07809256RecruitingPhase 3
Combination treatment for advanced lung cancer with a RET gene change
This trial tests a combination of two medicines (pembrolizumab and lenvatinib) for people with advanced non-small cell lung cancer that has a specific RET gene change. The treatment may help slow down or shrink the cancer, and the study checks how well people tolerate it.
Saint PetersburgAges 18 years+ - NCT07215416RecruitingPhase 1/Phase 2
Gene therapy for ataxia-telangiectasia with specific ATM mutation
This trial tests a new genetic medicine designed for people with A-T who have a specific ATM gene change. It aims to see if the treatment is safe and if it can improve symptoms.
Boston, MassachusettsAges birth–17 years - NCT03192501Recruiting
Using prior scans to guide cancer treatment choices
This trial tests whether using existing “PACS” scan images to guide individualized cancer treatment (compared with standard care) can improve outcomes for people with advanced or metastatic cancer. It may help doctors make more precise treatment decisions using your past imaging.
Guangzhou, GuangdongAges 18–70 - NCT07310485Enrolling by invitation
Soy supplements for premenstrual syndrome in women approaching menopause
This study tests whether taking phytoestrogens (plant-based compounds that act like estrogen) can reduce premenstrual syndrome symptoms and affect gene expression in healthy women in their 40s and 50s. It may help women who are still having regular periods but are approaching menopause.
Amman, Amman GovernorateAges 40–55 - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT07038213Enrolling by invitation
Study of kidney protection in type 2 diabetes
This study looks at how genes may affect kidney disease in people with type 2 diabetes. It tests treatments to protect the kidneys. If you are of Kazakh ethnicity and have type 2 diabetes, you may be able to join.
AstanaAges 18–65 - NCT03042221Recruiting
Early re-biopsy to find why tumors survive targeted drugs
This study takes a small tumor sample early after starting targeted treatment (or uses blood if a biopsy isn’t possible) to look for clues—called biomarkers—about why some tumor cells survive. The results may help improve how future patients’ treatments are chosen for certain lung cancer gene mutations.
Aurora, ColoradoAges 18–85 - NCT02716246RecruitingPhase 2/Phase 3
Gene therapy for MPS IIIA to slow brain decline
This trial tests a gene-transfer treatment (delivered into the spinal fluid) for children with MPS IIIA, a rare genetic condition. It aims to improve or slow down brain and developmental changes caused by a missing enzyme.
Columbus, OhioAges Any age - NCT02573636Recruiting
Testing genes in prostate cancer after radiation relapse
This study looks at specific gene changes (TMPRSS2-ERG fusion and PTEN deletion) in people whose prostate cancer returned after radiation. It aims to understand who may have a higher risk of relapse and help predict outcomes after salvage or radical radiation.
Chicoutimi, QuebecAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT06588322Recruiting
Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
AngersAges 18 years+ - NCT06087120Recruiting
Can a blood test predict breast cancer treatment response?
This study looks at whether a blood test (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. It focuses on people with HER2-positive or triple-negative breast cancer that has not spread far.
JakartaAges 18 years+ - NCT07432334RecruitingPhase 1
CAR T-cell therapy for hard-to-treat lupus
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
HanoiAges 16–55 - NCT04360265Enrolling by invitationPhase 3
Follow-up gene therapy study for MPS IIIA participants
This follow-up study looks at how a past gene therapy treatment (UX111) is affecting you over time. It mainly involves continued visits and safety checks, and it helps researchers understand long-term benefits and risks.
Columbus, OhioAges Any age - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05983159RecruitingPhase 2
Targeted therapy for slow-flow or fast-flow vascular malformations
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
Parkville, VictoriaAges 2 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+
Hear when a new Gene Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gene therapy?
- Yes. Clin2 currently lists 191 recruiting gene therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gene therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gene therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.